// App-Quantinova.ai

9073 : A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

Researchers

Presenter

  • Nikhil Shukla

Principal Investigators

  • Sandra K. Althouse

  • Susan Perkins

  • Muhammad Furqan

  • Ticiana Leal

  • Nasser H. Hanna

  • Greg Andrew Durm

Medical Centers

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Indiana University, Indianapolis, IN

  • University of Iowa Hospitals and Clinics, Iowa City, IA

  • University of Wisconsin Comprehensive Cancer Center, Madison, WI

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Pemetrexed

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03083808

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved